Obesity research has been transformed by the GLP-1 receptor agonist class (semaglutide, tirzepatide), which achieves 15–22% body weight reduction — approaching surgical outcomes — and reduces cardiovascular events in overweight adults. The pipeline now includes amylin analogs, glucose-dependent insulinotropic polypeptide (GIP) agonists, and oral small molecules targeting appetite regulation.
Active trials investigate next-generation GLP-1 combinations, bimagrumab (anti-ActRII for muscle-sparing weight loss), retatrutide, cagrilintide combinations, and gut microbiome modulators. Trials also study weight regain prevention after GLP-1 discontinuation — an emerging clinical challenge.
Obesity trials typically require a BMI ≥30 or ≥27 with weight-related comorbidities; prior bariatric surgery often excludes participants.
Frequently Asked Questions — overweight obesity Clinical Trials
How many clinical trials are currently recruiting for overweight obesity?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for overweight obesity, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for overweight obesity?
overweight obesity research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a overweight obesity clinical trial?
Eligibility criteria for overweight obesity trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Beijing Anzhen Hospital 1 trial
University of Colorado, Denver 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology